Remifentanil
Cross-source consensus on Remifentanil from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Interactions
Highlighted claims
- Remifentanil is an ultra-short-acting opioid hydrolysed by plasma and tissue esterases, producing non-cumulative analgesia with fast offset. — Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol
- The propofol-remifentanil combination carries a clinically significant risk of respiratory depression in paediatric patients. — Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol
- Remifentanil is the most widely used analgesic agent paired with propofol in paediatric procedural sedation. — Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol
- Prior opioid sedation history is recorded and classified to control for cumulative opioid tolerance as a confounding variable. — Safety and efficacy of esketamine versus remifentanil as adjuncts to propofol sedation in children undergoing haematologic-oncologic procedures in China: a single-centre, randomised, controlled, crossover trial protocol